To the Editor In JAMA Cardiology, Plitt et al1 provide an excellent overview on the pathophysiology linking diabetes and atrial fibrillation and on the mechanisms underlying the increased thromboembolic risk of patients presenting with both atrial fibrillation and diabetes. The authors emphasize the similar benefit of new oral anticoagulants (NOACs) on both stroke/systemic embolism and major bleeding compared with warfarin in patients with atrial fibrillation, regardless of the presence or absence of diabetes. We believe that the data on major bleeding deserve further attention.
Scridon A, Șerban RC. Major Bleeding in Patients With Diabetes and Atrial Fibrillation Treated With New Oral Anticoagulants. JAMA Cardiol. Published online June 28, 2017. doi:10.1001/jamacardio.2017.2031